Works Cited

1. Malamed SF. The chronicles of anesthesia: part 1. Dimens Dent Hyg. 2006;4(1):22-24.

2. Haas DA. An update on local anesthetics in dentistry. J Can Dent Assoc. 2002;68(9):546-551.

3. Webb L. Dental Anesthesia: Overview of Injectable Agents Useful for Nonsurgical Periodontal Therapy. Available at Last accessed August 13, 2018.

4. Henderson S. Drug interactions with local anaesthetic preparations used by primary care dental practitioners. Dent Update. 2010;37(4):236-238, 241.

5. Malamed SF. Up Close With Amide Anesthetic Agents. Available at Last accessed August 13, 2018.

6. Becker DE, Reed KL. Essentials of local anesthetic pharmacology. Anesth Prog. 2006;53(3):98-109.

7. Wynn RL, Meiller TF, Crossley HL. Drug Information Handbook for Dentistry. 24th ed. Hudson, OH: LexiComp; 2018.

8. Dembro JB. Articaine: anecdote and science. Todays FDA. 2009:21(4):15-17.

9. Malamed SF. Handbook of Local Anesthesia. 6th ed. St. Louis, MO: Mosby; 2012.

10. Uckan S, Dayangac E, Araz K. Is permanent maxillary tooth removal without palatal injection possible? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102(6):733-735.

11. Yadav S. Anesthetic success of supplemental infiltration in mandibular molars with irreversible pulpitis: a systematic review.J Conserv Dent. 2015;18(3):182-186.

12. Ashraf H, Kazem M, Dianat O, Noghrehkar F. Efficacy of articaine versus lidocaine in block and infiltration anesthesia administered in teeth with irreversible pulpitis: a prospective, randomized, double-blind study. J Endod. 2013;39(1):6-10.

13. Parirokh M, Yosefi MH, Nakhaee N, Abbott PV, Manochehrifar H. The success rate of bupivacaine and lidocaine as anesthetic agents in inferior alveolar nerve block in teeth with irreversible pulpitis without spontaneous pain. Restor Dent Endod. 2015;40(2):155-160.

14. Pogrel MA. Permanent nerve damage from the inferior alveolar nerve blocks: an update to include articaine. J Calif Dent Assoc. 2007;35(4):271-273.

15. Pogrel MA, Permanent nerve damage from inferior alveolar nerve blocks: a current update. J Calif Dent Assoc. 2012;40(10):795-797.

16. Kakroudi SH, Mehta S, Millar BJ. Articaine hydrochloride: is it the solution? Dent Update. 2015;42(1):88-90.

17. Yagiela JA. Local anesthetics. In: Dionne RA, Phero JP, Becker DE (eds). Management of Pain and Anxiety in the Dental Office: Oral and Maxillofacial. St. Louis, MO: WB Saunders; 2002.

18. LexiComp Online. Available at Last accessed August 13, 2018.

19. Kreeftenberg HG Jr, Braams R, Nauta P. Methemoglobinemia after low-dose prilocaine in an adult patient receiving barbiturate comedication. Anesth Analg. 2007;104(2):459-460.

20. MedicineNet. Acetaminophen Uses, Side Effects, and Dosage. Available at Last accessed August 13, 2018.

21. International Ibuprofen Foundation. Non-Prescription Use of Ibuprofen and the Risks of Gastrointestinal and Renal Toxicity. Available at Last accessed August 13, 2018.

22. FDA Makes Statement on Naproxen (Aleve). Available at Last accessed August 13, 2018.

23. Gutstein HB, Akil H. Opioid analgesics. In: Brunton LL, Lazo JS, Parker KL (eds). Goodman and Gilman's the Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill; 2006: 351-373.

24. Vree TB, van Dongen RT, Koopman-Kimenai PM. Codeine analgesia is due to codeine-6-glucuronide, not morphine. Int J Clin Pract. 2000;54(6):395-398.

25. Golubic S, Moore PA, Katz N, Kenna GA, Hersh EV. Opioid prescribing in dentistry: trends, ethical considerations, and diversion and abuse prevention. Inside Dent. 2011;7(6):51-58.

26. Denisco RC, Kenna GA, O'Neil MG, et al. Prevention of prescription opioid abuse: the role of the dentist. JADA. 2011;142(7):800-810.

27. McCauley JL, Leite RS, Gordan VV, et al. Opioid prescribing and risk mitigation implementation in the management of acute pain: results from The National Dental Practice-Based Research Network. J Am Dent Assoc. 2018;149(5):353-362.

28. McCauley JL, Leite RS, Melvin CL, Fillingim RB, Brady KT. Dental opioid prescribing practices and risk mitigation strategy implementation: identification of potential targets for provider-level intervention. Subst Abus. 2016;37(1):9-14.

29. Sinatra RS, Jahr JS, Watkins-Pitchford JM (eds). The Essence of Analgesia and Analgesics. Cambridge: Cambridge University Press; 2011.

30. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther. 2006;79(5):461-479.

31. Oxycodone. Available at Last accessed August 13, 2018.

32. Bellis M. The History of Penicillin. Available at Last accessed August 13, 2018.

33. Solensky R. Hypersensitivity reactions to beta-lactamantibiotics. Clin Rev Allergy Immunol. 2003;24(3):201-220.

34. Mailänder-Sánchez D, Wagener J, Schaller M. Potential role of probiotic bacteria in the treatment and prevention of localised candidosis. Mycoses. 2012;55(1):17-26.

35. PubChem Compound. Penicillin V. Available at Last accessed August 13, 2018.

36. Sandor GK, Low DE, Judd PL, Davidson RJ. Antimicrobial treatment options in the management of odontogenic infections.J Can Dent Assoc. 1998;64(7):508-514.

37. Topazian RG, Goldberg MH, Hupp JR (eds). Oral and Maxillofacial Infections. 4th ed. Philadelphia, PA: WB Saunders; 2002.

38. Public Health Agency of Canada. Human Antimicrobial Drug Use Report 2012/2013. Available at Last accessed August 13, 2018.

39. The Merck Manual. Lincosamides, Oxazolidinones and Streptogramins. Available at Last accessed August 13, 2018.

40. Newman MG, van Winkelhoff AJ (eds). Antibiotic and Antimicrobial Use in Dental Practice. 2nd ed. Chicago, IL: Quintessence; 2001.

41. Brook I, Lewis MA, Sándor GK, Jeffcoat M, Samaranayke LP, Vera Rojas J. Clindamycin in dentistry: more than just an effective prophylaxis for endocarditis? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100(5):550-558.

42. Mayo Clinic. Periodontitis. Available at Last accessed August 13, 2018.

43. RxList. Actisite. Available at Last accessed August 13, 2018.

44. Medical Wellness Center. Frequently Asked Questions: Periostat. Available at Last accessed August 13, 2018.

45. Arestin. Available at Last accessed August 13, 2018.

46. Centers for Disease Control and Prevention. Fungal Diseases. Candida Infections of the Mouth, Throat, and Esophagus: Statistics. Available at Last accessed August 13, 2018.

47. Berberi A, Noujeim Z, Aoun G. Epidemiology of oropharyngeal candidiasis in human immunodeficiency virus/acquired immune deficiency syndrome patients and CD4+ counts. J Int Oral Health. 2015;7(3):20-23.

48. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-e50.

49. American Dental Association. The ADA/PDR Guide to Dental Therapeutics. 5th ed. Montvale, NJ: PDR Network; 2009.

50. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA Limits Usage of Nizoral (ketoconazole) Oral Tablets Due to Potentially Fatal Liver Injury and the Risk of Drug Interactions and Adrenal Gland Problems. Available at Last accessed August 13, 2018.

51. World Health Organization. WHO Model List of Essential Medicines. Available at Last accessed August 13, 2018.

52. Little JW, Falace DA, Miller CS, Rhodus NL. Little and Falace's Dental Management of the Medically Compromised Patient. 8th ed. St. Louis, MO: Mosby; 2012. 9th ed. St. Louis, MO: Mosby; 2018.

53. Donaldson M, Goodchild JH. Maximum cumulative doses of sedation medication for in-office use. Gen Dent. 2007;55(2):143-148.

54. Farinde A. Benzodiazepine Equivalency Table. Available at Last accessed August 13, 2018.

55. Goerig M, Schulte am Esch J. History of nitrous oxide with special reference to its early use in Germany. Best Pract Res Clin Anesthesiol. 2001;15(3):313-338.

56. Dental Assisting National Board, Inc. California State Requirements. Additional Resources. Allowable and Prohibited Duties for Each Level (PDF). Available at Last accessed August 13, 2018.

57. Goldhirsch A, Gelber RD, Tattersall MN, Rudenstam CM, Cavalli F. Methotrexate/nitrous-oxide toxic interaction in perioperative chemotherapy for early breast cancer. Lancet. 1987;2(8551):151.

58. van Outryve S, Schrijvers D, van den Brande J, et al. Methotrexate-associated liver toxicity in a patient with breast cancer: case report and literature review. Neth J Med. 2002;60(5):216-222.

59. Silverman M, Hexem J. Nitrous oxide/oxygen sedation and the single-dose sedative. Inside Dent. 2011;7(8):42-54.

60. Federal Register. Content and Format of Labeling for Human Prescription Drug and Biological Products: Requirements for Pregnancy and Lactation Labeling. Available at Last accessed August 13, 2018.

61. Gaffney A. FDA Scraps Pregnancy Labeling Classification System in Favor of New Standard. Available at Last accessed August 13, 2018.

62. U.S. Food and Drug Administration. Pregnancy and Lactation Labeling Final Rule. Available at Last accessed August 13, 2018.

63. U.S. Food and Drug Administration. Press Release. FDA Issues Final Rule on Changes to Pregnancy and Lactation Labeling Information for Prescription Drug and Biological Products. Available at Last accessed August 13, 2018.

Evidence-Based Practice Recommendations Citations

1. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1-e48. Available at Last accessed August 20, 2018.

Copyright © 2018 NetCE, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.